



EUSA PHARMA APPOINTS PRESIDENT EUROPE

Doylestown PA, USA and Oxford, UK - 3 October 2007 – EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Ad van Beysterveldt as President Europe and member of the company's Executive Committee.

Ad van Beysterveldt, 52, joins the company from Cephalon where he led the European oncology franchise. He brings 30 years' commercial and managerial experience, having held many senior roles in the pharmaceutical industry, largely at Bristol-Myers Squibb. With significant international experience he has extensive knowledge of the European, US and Asian markets, particularly in the fields of oncology and critical care. Mr van Beysterveldt succeeds Jim Phillips as EUSA's President Europe. Ad holds a degree in Law and Economics from University Brabant, The Netherlands.

"I am delighted to welcome Ad to EUSA during this period of rapid growth for the company," said **Bryan Morton, Chief Executive of EUSA Pharma**. "Attracting a senior executive of Ad's caliber is a real demonstration of the progress we are making toward becoming a leading transatlantic specialty pharmaceutical company with a world-class commercial infrastructure. Ad's intimate understanding of the European marketplace, and expertise in the oncology and critical care fields, will prove a real asset for EUSA as we continue to grow our business on both sides of the Atlantic."

"Having had the privilege to work with a number of EUSA's senior executives previously, I am convinced that the team has the expertise and drive needed to establish one of the pharmaceutical industry's up-and-coming companies," said **Ad van Beysterveldt, President Europe of EUSA Pharma**. "Backed by world-class investors, EUSA is building a strong and profitable business and I look forward to leading our European operations as we continue to execute the company's ambitious growth plans."

---ENDS---

About EUSA Pharma Inc

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has six products on the market, including the antibiotic surgical implant Collatamp[®] G, Erwinase[®] and Kidrolase[®] for the treatment of acute lymphoblastic leukemia, and Rapydan[™], a rapid-onset anesthetic patch for which EUSA expects to receive Europe-wide approval in 2007. EUSA also has several products in late-stage development, notably Collatamp[®] G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx[®] bupivacaine implant for local post-surgical pain control.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over \$225 million and completed a number of significant transactions, including the acquisitions of Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control



business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US and Canada, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to maintain a strong focus on acquisitions and in-licensing within its specialist medical and geographic areas, in line with its ambition to create a \$1 billion company by the first half of the next decade.

For more information please visit www.eusapharma.com.

Contacts

EUSA Pharma UK

Bryan Morton, Chief Executive

+44 (0) 1865 784 255

Financial Dynamics

Julia Phillips / Emma Thompson

+44 (0) 20 7831 3113